Literature DB >> 33208083

Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country.

Sherief Abd-Elsalam1, Eslam Saber Esmail1, Mai Khalaf1, Ghada N El-Sarnagawy2, Shahinaz M Shalaby3, Mohamed Samir Abd El Ghafar4, Mohamed Elbahnasawy5, Asem Elfert1, Hanan Soliman1, Ferial El-Kalla1, Ahmed Ghoneim6.   

Abstract

In late 2019, SARS-COV-2 disease was firstly discovered in Wuhan, China and then it infected millions of people worldwide. Later, the World Health Organization (WHO) described COVID-19 as the first pandemic invading the world in the 21st century. The WHO has declared that the emerging infection will last long enough to force adjustments not only in people's lifestyles but also in the health care system. This amendment is expected to spread through many medical practices and specialties. A lot of diagnostic and therapeutic modalities have been proposed for COVID-19 management. The best strategy for the management of patients requires a multi-disciplinary team approach with correct decisions regarding the right timing of each modality of treatment. The participating multidisciplinary team for COVID-19 management includes six infectious diseases experts in Tanta University; one critical care management expert, an emergency medicine expert and two pharmacists in Tanta University. In this review, we reported our multi-disciplinary team experience with up to date literature guidance to propose a valid protocol for the management of COVID-19 patients in a limited resources setting. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Coronavirus infection; PCR; chloroquine.; diagnosis; serology; treatment

Mesh:

Year:  2021        PMID: 33208083     DOI: 10.2174/1871530320999201117142305

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  2 in total

1.  Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.

Authors:  Hany M Dabbous; Sherief Abd-Elsalam; Manal H El-Sayed; Ahmed F Sherief; Fatma F S Ebeid; Mohamed Samir Abd El Ghafar; Shaimaa Soliman; Mohamed Elbahnasawy; Rehab Badawi; Mohamed Awad Tageldin
Journal:  Arch Virol       Date:  2021-01-25       Impact factor: 2.574

2.  Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.

Authors:  Sherief Abd-Elsalam; Rasha A Noor; Rehab Badawi; Mai Khalaf; Eslam S Esmail; Shaimaa Soliman; Mohamed S Abd El Ghafar; Mohamed Elbahnasawy; Ehab F Moustafa; Sahar M Hassany; Mohammed A Medhat; Haidi Karam-Allah Ramadan; Maii A S Eldeen; Mohamed Alboraie; Ahmed Cordie; Gamal Esmat
Journal:  J Med Virol       Date:  2021-06-07       Impact factor: 20.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.